DeepHealth Unveils Comprehensive Portfolio of Native Clinical AI Solutions

DeepHealth, a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, unveils at ECR 2026 the industry's most comprehensive portfolio of native clinical AI solutions and services across all core imaging modalities — MR, CT, X-ray, Mammography and Ultrasound — and spanning detection, assessment and monitoring, all available on one platform. With this week’s acquisition of Gleamer, DeepHealth further expands its leadership in advancing screening tools into routine imaging and acute diagnostic care, uniquely positioned to deliver the next era of AI-powered health informatics. 

"As European nations scale their screening ambitions and confront rising workload pressures, our integrated portfolio is designed to stage shift disease, empower diagnostic excellence and expand patient access, thereby driving precision care," said Niccolo Stefani, MD, Business Leader Population Health & Clinical AI, DeepHealth.  "These solutions transform imaging pathways, enabling healthcare systems to move from reactive treatment to proactive intervention while addressing the realities of diverse European markets, to improve patient outcomes."  

DeepHealth’s expanded European portfolio now delivers a fully integrated, end-to-end suite of modular AI solutions, validated by clinical evidence and proof at scale in real-world settings. Designed to stage-shift disease through earlier detection, the portfolio enhances diagnostic consistency while driving meaningful gains in operational efficiency.